Publication | Open Access

Selumetinib in paediatric patients with BRAF-aberrant or neurofibromatosis type 1-associated recurrent, refractory, or progressive low-grade glioma: a multicentre, phase 2 trial

Neuro-oncologyTumoral PathologyPediatric Brain TumorsProgressive Low-grade GliomaMedicinePathologyBrain Tumor BiologyNeurologyHigh-grade GliomasBrain LesionPaediatric PatientsNeuropathologyOncologyGliomaPhase 2